129 related articles for article (PubMed ID: 2522561)
1. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.
de Voogt HJ; Suciu S; Sylvester R; Pavone-Macaluso M; Smith PH; de Pauw M
J Urol; 1989 Apr; 141(4):883-8. PubMed ID: 2522561
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
de Voogt HJ; Smith PH; Pavone-Macaluso M; de Pauw M; Suciu S
J Urol; 1986 Feb; 135(2):303-7. PubMed ID: 2935644
[TBL] [Abstract][Full Text] [Related]
4. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
5. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
6. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
7. Hormonal therapy of advanced prostatic cancer.
Fair WR
J Urol; 1986 Sep; 136(3):653-4. PubMed ID: 2942708
[No Abstract] [Full Text] [Related]
8. Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
Bollack C; Rougeron G
Am J Clin Oncol; 1988; 11 Suppl 2():S156-9. PubMed ID: 2977270
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
[No Abstract] [Full Text] [Related]
10. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
11. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
[TBL] [Abstract][Full Text] [Related]
12. Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder FH
Prostate; 1984; 5(2):193-8. PubMed ID: 6231535
[TBL] [Abstract][Full Text] [Related]
13. Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
deVoogt HJ; Pavone-Macaluso M; Sylvester R; Schröder FH
J Urol; 1988 Dec; 140(6):1557. PubMed ID: 2973530
[No Abstract] [Full Text] [Related]
14. Is there a best endocrine management of prostatic carcinoma?
Robinson MR
Prog Clin Biol Res; 1988; 269():147-58. PubMed ID: 2969114
[No Abstract] [Full Text] [Related]
15. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
Burgos FJ; Maganto E; Jiménez M; Mayayo T; Allona A; Mateos A; Escudero A; Romero-Aguirre C
Actas Urol Esp; 1988; 12(6):500-6. PubMed ID: 3232555
[No Abstract] [Full Text] [Related]
17. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Hauchecorne J
Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
[No Abstract] [Full Text] [Related]
18. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Benson RC; Cummings K
Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
[No Abstract] [Full Text] [Related]
19. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
20. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
